查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600569

癌症/肿瘤分析市场：按技术、生物标记类型、癌症类型、应用划分 - 2025-2030 年全球预测

Cancer/Tumor Profiling Market by Technology (Immunoassays, In-Situ Hybridization, Mass Spectrometry), Biomarker Type (Genomic Biomarker, Protein Biomarker), Cancer Type, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年癌症/肿瘤分析市值为107.9亿美元，预计到2024年将达到127.7亿美元，复合年增长率为18.74%，到2030年将达到359.4亿美元。

癌症/肿瘤分析在遗传和分子层面上对癌细胞进行全面分析，以了解肿瘤异质性的复杂性并促进个人化治疗策略。癌症分析的需求源于其在精准医学中的重要作用，使肿瘤学家能够根据个别生物标记物定制治疗方案，改善治疗结果并最大限度地减少副作用。其应用涵盖临床诊断、药物发现和肿瘤学研究，最终用户为医院、诊断实验室、研究机构和製药公司。市场成长的主要驱动力是癌症盛行率的增加、次世代定序（NGS）等分析技术的进步以及对个人化医疗的需求不断增长。特别是，向高通量技术的转变和具有成本效益的分析方法的开发为行业扩张提供了重大机会。此外，製药公司和技术开发公司之间为增强标靶治疗结成的联盟可能会推动市场成长。然而，与先进定序平台相关的挑战，例如高成本、资料隐私问题和缺乏熟练的专业人员，是主要障碍。此外，监管复杂性和报销问题也构成了额外的障碍。潜在的创新领域在于开发整合生物资讯解决方案和人工智慧主导的分析，以增强资料解释和预测建模。扩大液态切片和非侵入性分析方法的研究和开发工作可以为投资者和开发商开闢新的视野。市场正在动态发展，并且存在跨学科合作的趋势，以利用全面的资料集来获得可靠的临床见解。为了利用新的商业机会，相关人员应专注于提高分析技术的可近性和可负担性，建立策略联盟，并投资人才发展计画以缩小技能差距。将透过促进符合全球监管格局并满足癌症治疗的多样化需求的创新来实现永续成长。

主要市场统计
基准年[2023] 107.9亿美元
预测年份 [2024] 127.7亿美元
预测年份 [2030] 359.4亿美元
复合年增长率（%） 18.74%

市场动态：揭示快速发展的癌症/肿瘤分析市场的关键市场洞察

供需的动态交互作用正在改变癌症/肿瘤分析市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 在癌症患者治疗中更多地采用生物标记
    • 政府机构和全球组织倡议开发癌症诊断的可用性
    • 癌症治疗中个人化医疗越来越偏好
  • 市场限制因素
    • 癌症/肿瘤分析设备和服务的高资本投资
  • 市场机会
    • 次世代定序仪的出现和肿瘤分析的进展
    • 改进照护现场诊断技术以改善癌症检测
  • 市场挑战
    • 生物标誌物的发现和核准率较低

波特五力：驾驭癌症/肿瘤分析市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解癌症/肿瘤分析市场的外部影响

外部宏观环境因素在塑造癌症/肿瘤分析市场的绩效动态方面发挥关键作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解癌症/肿瘤分析市场的竞争格局

癌症/肿瘤分析市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵癌症/肿瘤分析市场供应商的绩效评估

FPNV定位矩阵是评估癌症/肿瘤分析市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 在癌症患者的治疗中更多地采用生物标记
      • 各国政府和国际组织为开发癌症诊断方法所做的努力
      • 人们对癌症治疗中的个人化医疗越来越感兴趣
    • 抑制因素
      • 对癌症/肿瘤分析设备和服务的大量资本投资
    • 机会
      • 次世代定序的出现和肿瘤分析的进展
      • 改进照护现场诊断技术以改善癌症检测
    • 任务
      • 生物标誌物的发现率和核准较低
  • 市场区隔分析
    • 技术：使用次世代定序(NGS) 寻找各种癌症的基因突变
    • 生物标记的类型：基因生物标誌物用于测量基因表现、基因功能和基因调控。
    • 癌症类型：广泛推荐用于预测模型和临床风险分层的前列腺癌癌症分析
    • 应用：在开发精准医学中增加使用癌症/肿瘤分析来缩短癒合和恢復时间
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章癌症/肿瘤分析市场：依技术分类

  • 免疫检测
  • 原位杂交
  • 质谱分析
  • 微阵列
  • 次世代定序
  • 聚合酵素链锁反应

第 7 章按生物标记类型分類的癌症/肿瘤分析市场

  • 基因生物标誌物
  • 蛋白质生物标记

第 8 章按癌症类型分類的癌症/肿瘤分析市场

  • 乳癌
  • 大肠直肠癌
  • 肺癌
  • 黑色素瘤癌症
  • 摄护腺癌

第九章癌症/肿瘤分析市场：依应用分类

  • 生物标记发现
  • 临床应用
  • 诊断
  • 个人化医疗
  • 预言
  • 调查
  • 筛检
  • 治疗和监测

第10章美洲癌症/肿瘤分析市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太癌症/肿瘤分析市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的癌症/肿瘤分析市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 安捷伦与 NCCS 签署研究合作协议，推动新加坡亚洲常见癌症的基因组分析
    • Sophia Genetics 与安捷伦合作开发癌症分析产品
    • Point32Health 和 Foundation Medicine 扩大了晚期癌症患者全面基因组分析的范围
    • 协同效应 Laboratories 选择 SOPHiA GENETICS 技术用于新的癌症分析解决方案
    • Exact Sciences 在美国推出 OncoExTra 癌症治疗选择测试
    • Caris Life Sciences 筹集了 4 亿美元，使总资金筹措接近 20 亿美元
    • Prenetics 旗下 ACT Genomics 的 ACTOnco 获得 FDA 批准
    • 安捷伦宣布收​​购用于癌症研究的高性能 NGS靶向序列捕获工作流程开发商 Avida Biomed
    • Prenetics 收购 ACT Genomics
    • 罗氏首个伴同性诊断获得 FDA核准，用于识别符合 Enhartu 资格的 HER2 低转移性乳癌患者
    • CDC 拨款 2.15 亿美元推动癌症登月目标

公司名单

  • Takara Bio Inc.
  • Nonacus Limited
  • GenScript Biotech Corporation
  • Tempus Labs Inc.
  • Thermo Fisher Scientific Inc.
  • Hologic, Inc.
  • 4basecare Onco Solutions Private Limited
  • Personalis, Inc.
  • Merck KGaA
  • Exact Sciences Corporation
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Lucence Health, Inc.
  • Guardant Health, Inc.
  • Sysmex Corporation
  • Agendia, Inc.
  • Paragon Genomics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • HTG Molecular Diagnostics, Inc.
  • NanoString Technologies, Inc.
  • Predictive Oncology Inc.
  • IMBdx, Inc.
  • Perthera, Inc.
  • GENINUS Inc.
  • Genomic Life
  • ACT Genomics Co., Ltd. by Prenetics Global Limited
  • BostonGene Corporation
  • Caris Life Sciences
  • Strand Life Sciences
  • Neogenomics, Inc.
  • Agilent Technologies, Inc.
  • Oncompass Medicine Hungary Kft.
  • OncoDNA SA
Product Code: MRR-374DB5A06C7F

The Cancer/Tumor Profiling Market was valued at USD 10.79 billion in 2023, expected to reach USD 12.77 billion in 2024, and is projected to grow at a CAGR of 18.74%, to USD 35.94 billion by 2030.

Cancer/tumor profiling encompasses a comprehensive analysis of the cancerous cells at a genetic and molecular level, which aids in understanding the complexities of tumor heterogeneity and facilitates personalized treatment strategies. The necessity of cancer profiling arises from its critical role in precision medicine, enabling oncologists to tailor treatments based on individual biomarkers, thus improving therapeutic outcomes and minimizing adverse effects. Its applications span across clinical diagnostics, drug discovery, and oncology research, with end-users comprising hospitals, diagnostic laboratories, research institutes, and pharmaceutical companies. Market growth is primarily driven by the increasing prevalence of cancer, advancements in profiling technologies such as next-generation sequencing (NGS), and heightened demand for personalized medicine. Particularly, the shift towards high-throughput technologies and the development of cost-effective profiling methods present vast opportunities for industry expansion. Additionally, partnerships between pharmaceutical firms and technology developers to enhance targeted therapies could fuel market growth. However, challenges such as high costs associated with advanced sequencing platforms, data privacy concerns, and a dearth of skilled professionals act as significant hindrances. Furthermore, regulatory complexities and reimbursement issues pose additional barriers. Potential areas of innovation lie in the development of integrated bioinformatics solutions and AI-driven analytics to enhance data interpretation and predictive modeling. Expanding R&D efforts in liquid biopsy and non-invasive profiling methods could open new vistas for investors and developers alike. The market is dynamic and evolving, with a trend towards cross-disciplinary collaboration to leverage comprehensive datasets for robust clinical insights. To capitalize on emerging opportunities, stakeholders should focus on enhancing the accessibility and affordability of profiling techniques, building strategic alliances, and investing in workforce training programs to bridge the skill gap. Sustainable growth could be realized by fostering innovations that align with global regulatory standards and meet the diverse needs of the oncology treatment landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 10.79 billion
Estimated Year [2024] USD 12.77 billion
Forecast Year [2030] USD 35.94 billion
CAGR (%) 18.74%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer/Tumor Profiling Market

The Cancer/Tumor Profiling Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing adoption of biomarkers to treat cancer patients
    • Availability of government and global organizations' initiatives for devising cancer diagnosing methods
    • Surging preference for personalized medicines for cancer treatment
  • Market Restraints
    • High capital investment in cancer/tumor profiling instruments and services
  • Market Opportunities
    • Emergence of next-generation sequencing and advancements in tumor profiling
    • Improvements in point-of-care diagnostic technologies to improve cancer detection
  • Market Challenges
    • Low biomarker discovery-to-approval ratio

Porter's Five Forces: A Strategic Tool for Navigating the Cancer/Tumor Profiling Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer/Tumor Profiling Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer/Tumor Profiling Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer/Tumor Profiling Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer/Tumor Profiling Market

A detailed market share analysis in the Cancer/Tumor Profiling Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer/Tumor Profiling Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer/Tumor Profiling Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Cancer/Tumor Profiling Market, highlighting leading vendors and their innovative profiles. These include Takara Bio Inc., Nonacus Limited, GenScript Biotech Corporation, Tempus Labs Inc., Thermo Fisher Scientific Inc., Hologic, Inc., 4basecare Onco Solutions Private Limited, Personalis, Inc., Merck KGaA, Exact Sciences Corporation, Illumina, Inc., Laboratory Corporation of America Holdings, Lucence Health, Inc., Guardant Health, Inc., Sysmex Corporation, Agendia, Inc., Paragon Genomics, Inc., F. Hoffmann-La Roche Ltd., HTG Molecular Diagnostics, Inc., NanoString Technologies, Inc., Predictive Oncology Inc., IMBdx, Inc., Perthera, Inc., GENINUS Inc., Genomic Life, ACT Genomics Co., Ltd. by Prenetics Global Limited, BostonGene Corporation, Caris Life Sciences, Strand Life Sciences, Neogenomics, Inc., Agilent Technologies, Inc., Oncompass Medicine Hungary Kft., and OncoDNA S.A..

Market Segmentation & Coverage

This research report categorizes the Cancer/Tumor Profiling Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Immunoassays, In-Situ Hybridization, Mass Spectrometry, Microarrays, Next-Generation Sequencing, and Polymerase Chain Reaction.
  • Based on Biomarker Type, market is studied across Genomic Biomarker and Protein Biomarker.
  • Based on Cancer Type, market is studied across Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma Cancer, and Prostate Cancer.
  • Based on Application, market is studied across Biomarker Discovery, Clinical Application, Diagnostics, Personalized Medicine, Prognostics, Research, Screening, and Treatment & Monitoring.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing adoption of biomarkers to treat cancer patients
      • 5.1.1.2. Availability of government and global organizations' initiatives for devising cancer diagnosing methods
      • 5.1.1.3. Surging preference for personalized medicines for cancer treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High capital investment in cancer/tumor profiling instruments and services
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of next-generation sequencing and advancements in tumor profiling
      • 5.1.3.2. Improvements in point-of-care diagnostic technologies to improve cancer detection
    • 5.1.4. Challenges
      • 5.1.4.1. Low biomarker discovery-to-approval ratio
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Adoption of next-generation sequencing (NGS) for exploring genetic alterations in various cancers
    • 5.2.2. Biomarker Type: Use of genomic biomarkers for the measurement of the expression of a gene, the gene function, and the gene regulation
    • 5.2.3. Cancer Type: Wide preference for cancer profiling in prostate cancers for predictive modeling and clinical risk stratification
    • 5.2.4. Application: Increasing use of cancer/tumor profiling in developing precision medicine to improve healing and recovery time
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer/Tumor Profiling Market, by Technology

  • 6.1. Introduction
  • 6.2. Immunoassays
  • 6.3. In-Situ Hybridization
  • 6.4. Mass Spectrometry
  • 6.5. Microarrays
  • 6.6. Next-Generation Sequencing
  • 6.7. Polymerase Chain Reaction

7. Cancer/Tumor Profiling Market, by Biomarker Type

  • 7.1. Introduction
  • 7.2. Genomic Biomarker
  • 7.3. Protein Biomarker

8. Cancer/Tumor Profiling Market, by Cancer Type

  • 8.1. Introduction
  • 8.2. Breast Cancer
  • 8.3. Colorectal Cancer
  • 8.4. Lung Cancer
  • 8.5. Melanoma Cancer
  • 8.6. Prostate Cancer

9. Cancer/Tumor Profiling Market, by Application

  • 9.1. Introduction
  • 9.2. Biomarker Discovery
  • 9.3. Clinical Application
  • 9.4. Diagnostics
  • 9.5. Personalized Medicine
  • 9.6. Prognostics
  • 9.7. Research
  • 9.8. Screening
  • 9.9. Treatment & Monitoring

10. Americas Cancer/Tumor Profiling Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cancer/Tumor Profiling Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cancer/Tumor Profiling Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Agilent and NCCS Sign Research Collaboration Agreement to Advance Singapore's Genomic Profiling on Asian-prevalent Cancers
    • 13.3.2. Sophia Genetics, Agilent Partner on Cancer Analysis Product
    • 13.3.3. Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer
    • 13.3.4. Synergy Laboratories Taps SOPHiA GENETICS Technology for New Cancer Profiling Solution
    • 13.3.5. Exact Sciences Launches OncoExTra Cancer Therapy Selection Test in the U.S.
    • 13.3.6. Caris Life Sciences nears USD 2B in total funding with USD 400M haul
    • 13.3.7. Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco
    • 13.3.8. Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
    • 13.3.9. Prenetics Acquires ACT Genomics
    • 13.3.10. Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for Enhertu
    • 13.3.11. CDC Awards USD 215 Million to Advance Cancer Moonshot Goals

Companies Mentioned

  • 1. Takara Bio Inc.
  • 2. Nonacus Limited
  • 3. GenScript Biotech Corporation
  • 4. Tempus Labs Inc.
  • 5. Thermo Fisher Scientific Inc.
  • 6. Hologic, Inc.
  • 7. 4basecare Onco Solutions Private Limited
  • 8. Personalis, Inc.
  • 9. Merck KGaA
  • 10. Exact Sciences Corporation
  • 11. Illumina, Inc.
  • 12. Laboratory Corporation of America Holdings
  • 13. Lucence Health, Inc.
  • 14. Guardant Health, Inc.
  • 15. Sysmex Corporation
  • 16. Agendia, Inc.
  • 17. Paragon Genomics, Inc.
  • 18. F. Hoffmann-La Roche Ltd.
  • 19. HTG Molecular Diagnostics, Inc.
  • 20. NanoString Technologies, Inc.
  • 21. Predictive Oncology Inc.
  • 22. IMBdx, Inc.
  • 23. Perthera, Inc.
  • 24. GENINUS Inc.
  • 25. Genomic Life
  • 26. ACT Genomics Co., Ltd. by Prenetics Global Limited
  • 27. BostonGene Corporation
  • 28. Caris Life Sciences
  • 29. Strand Life Sciences
  • 30. Neogenomics, Inc.
  • 31. Agilent Technologies, Inc.
  • 32. Oncompass Medicine Hungary Kft.
  • 33. OncoDNA S.A.

LIST OF FIGURES

  • FIGURE 1. CANCER/TUMOR PROFILING MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER/TUMOR PROFILING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CANCER/TUMOR PROFILING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CANCER/TUMOR PROFILING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER/TUMOR PROFILING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER/TUMOR PROFILING MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IN-SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENOMIC BIOMARKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEIN BIOMARKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MELANOMA CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TREATMENT & MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 88. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 116. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 117. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 121. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 137. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 141. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 153. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 157. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 165. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SPAIN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 177. SPAIN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SPAIN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SPAIN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. SWEDEN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 181. SWEDEN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SWEDEN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. SWEDEN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. SWITZERLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. SWITZERLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. SWITZERLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. TURKEY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 189. TURKEY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. TURKEY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. TURKEY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED ARAB EMIRATES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED ARAB EMIRATES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. CANCER/TUMOR PROFILING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 201. CANCER/TUMOR PROFILING MARKET, FPNV POSITIONING MATRIX, 2023